Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:sneaker
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Lucentis
|
| gptkbp:approves |
gptkb:2019
|
| gptkbp:clinical_trial |
Phase III
retinal diseases CAY-2001 CAY-2002 CAY-2003 |
| gptkbp:contraindication |
active ocular infections
hypersensitivity to brolucizumab uncontrolled systemic conditions |
| gptkbp:dosage_form |
solution for injection
every 8 to 12 weeks |
| gptkbp:education |
follow-up appointments are crucial
report any vision changes understand injection procedure |
| gptkbp:effective_date |
October 2019
|
| gptkbp:formulation |
gptkb:brolucizumab_injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Beovu
|
| gptkbp:indication |
wet AMD
|
| gptkbp:ingredients |
gptkb:brolucizumab
|
| gptkbp:invention |
gptkb:Novartis_AG
|
| gptkbp:is_monitored_by |
visual acuity
intraocular pressure ocular health |
| gptkbp:is_used_for |
treatment of wet age-related macular degeneration
|
| gptkbp:lifespan |
approximately 14 days
|
| gptkbp:manager |
intravitreal injection
intravitreal |
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
VEGF inhibitor
systemic exposure low |
| gptkbp:research |
studies on combination therapies
studies on safety profile ongoing studies for other retinal diseases studies on long-term efficacy studies on patient quality of life |
| gptkbp:safety_features |
risk of serious eye problems
|
| gptkbp:side_effect |
floaters
vision loss eye pain increased intraocular pressure intraocular inflammation hypersensitivity reactions ocular inflammation cataract formation retinal vasculitis |
| gptkbp:storage |
refrigerated at 2° C to 8° C
|